Skip to main content

Washington Is Fighting Over Who Gets Credit for the Overdose Decline. Medicaid Will Decide Whether It Lasts.

Nearly 47,000 fewer Americans a year are dying of overdoses than at the peak. The White House says that's its win, NPR says the math says otherwise, and the people who actually did the work are six weeks from a Medicaid paperwork wall.

ByThe Rize NewsroomNovember 20, 20269 min readOpioids

Charlie Cromartie knows the sound of a hold queue better than she knows most songs. For years she called treatment programs on behalf of her 33-year-old son, who uses fentanyl and methamphetamine and has survived more than one overdose. She told WSOC-TV in Charlotte this week what those calls were like: “I get the hang-ups. I get the long hold times. I get the, ‘Oh, we’re going to call you back.’ Never call me back.” What finally worked was not a slogan or a border operation. It was a county-funded team of peer specialists at Atrium Health that promises to reach someone within 24 hours of a referral — and a woman on that team, Jennifer Oram, who could tell him she had been through “multiple rehabs, multiple detoxes” herself.

Hold that picture, because Washington spent this week arguing about who deserves credit for people like her son still being alive.

The overdose decline was built by Medicaid cards, naloxone and people like Jennifer Oram — and the government claiming credit for it is about to make all three harder to reach.

The numbers are real and they are good. The CDC’s provisional overdose counts, updated November 10, predict 65,724 deaths in the 12 months ending June 2026. At the peak — the 12 months ending August 2023 — the same CDC dataset counted 112,418. That is a 41.5% drop: roughly 46,700 fewer funerals a year. If you are reading this and you have buried someone, you know exactly how big a number that is, and exactly how little it fixes. Both things are true at once.

The credit fight is a fight about the wrong thing

On November 16, the White House drug policy office put out a release headlined around “the 18th consecutive month” of decline. ONDCP Director Sara Carter said “America is unequivocally winning the fight against illicit drugs,” and the release lined up the year-over-year drops: synthetic opioids down 18.7%, psychostimulants down 14.1%, cocaine down 6.3%. Those figures match the CDC data. The framing does not.

Two days later NPR’s Brian Mann laid out the timeline the release left out. The decline started in 2023 and had already cut fatal overdoses by about a third by the time President Biden left office. “Since the spring of 2023, we have seen a steady decline in overdose deaths,” Vanda Felbab-Brown of the Brookings Institution told him. Asked about the administration’s emphasis on cartels-as-terrorists, she was blunter: “I cannot think of one narco-terrorist organization that has been dismantled.” Carter’s answer to NPR was that the previous administration “doesn’t get to take credit for overseeing the highest drug overdose numbers in history, then bringing them down from their own failure.”

Here is the honest version, and nobody in this fight wants to say it: no president caused this decline, and no president can keep it going by press release. The experts NPR interviewed describe a pile of overlapping causes, and so does the plain timeline: naloxone everywhere, more people on buprenorphine and methadone, a drug supply that shifted in ways nobody fully understands, and a generation of younger people who watched fentanyl kill their older siblings and stayed away from it. Nabarun Dasgupta, who studies the street drug supply at UNC-Chapel Hill, told NPR the steepest stretch was “early 2024 through spring 2025.” That is a timeline that straddles two administrations, which is another way of saying it belongs to neither.

The credit fight matters for one reason only: whoever believes they won the war gets to decide what to cut. If you think the decline came from fentanyl seizures and border posture, then the boring civilian machinery — Medicaid enrollment, peer specialists, test strips, methadone clinics — looks like overhead. And that machinery is exactly what is on the table right now.

We have watched a country misread a drug decline before

In the early 1990s, crack use in New York City started to fall, and every politician with a podium claimed it. Tougher sentences, more arrests, the 100-to-1 sentencing disparity between crack and powder cocaine that Congress wrote into law in 1986 — all of it got the credit. Then federal researchers went and asked. A 1997 National Institute of Justice study by Andrew Golub and Bruce Johnson found that the epidemic in New York “entered a decline around 1990 when youths began to disdain crack use.” Kids had watched what crack did to the people a few years older than them and decided they wanted no part of it. Enforcement did not end the crack era. Younger people did. The country drew the wrong lesson anyway, kept the sentencing laws for another 24 years, and filled prisons on the strength of a story that wasn’t true.

Tougher sentences, more arrests, the 100-to-1 sentencing disparity between crack and powder cocaine that Congress wrote into law in 1986 — all of it got the credit.

The pattern is the same now: a decline with many authors gets assigned to whoever holds the microphone, and the policy that follows is built on the misreading. The difference this time is that the things the misreading puts at risk are the things that keep people alive between their worst night and their first appointment. You can see the early version of it already. KFF Health News reported this week that North Carolina’s state opioid program relied on SAMHSA as its only source of fentanyl and xylazine test strips — the source that dried up when federal policy turned against them. “It’s just a hard time right now, because of politics, and politics should never get in the way of saving lives,” Kaya Littleturtle of the Good Mind Initiative told the outlet. We covered the Southwest lagging behind the national decline earlier this week; the national good news has never been evenly spread, and the cuts won’t be either.

January 1 is the date that matters, not November 16

The policy calendar is more important than the press calendar. Under last year’s reconciliation law, Medicaid work requirements for adults in the expansion population begin January 1, 2027 — six weeks from now. People with substance use disorders are supposed to be exempt under the law’s “medically frail” category, and people in treatment are supposed to be protected. “Supposed to be” is doing a lot of work in that sentence. An exemption you have to document is an exemption that gets lost in a mailbox, a disconnected phone, or a shelter address that changed in October. Anyone who has tried to get a benefits office to call them back already knows how that goes — Charlie Cromartie certainly does.

Dasgupta said it plainly to NPR: “Medicaid is the largest funder of addiction services in the United States… Cutting Medicaid eligibility or making it harder to access forms of effective addiction treatment is guaranteed to leave people out in the cold.” NPR’s reporting also cites the Congressional Budget Office estimate that up to 10 million Americans could lose insurance as the law takes hold.

There is one small mercy on the table. On November 13 the federal Medicaid agency offered states an optional “hold harmless” period through June 30, 2027, during which they can choose not to deny or drop people solely for failing the work requirement. California announced on November 19 that it will take it, promising that applicants “would not be denied Medi-Cal solely for failing to meet the work and community engagement requirements” while the state builds its systems. Every state can make that choice. As of this writing we found no public announcement that Arizona’s AHCCCS will — and Arizona, where we work, is one of the states where this decision lands hardest.

Congress, meanwhile, is quietly declining to blow up the agency doing the work. The Senate’s FY27 Labor-HHS bill, summarized by ASTHO on November 19, funds SAMHSA at about $7.5 billion — an increase of roughly $18 million — and does not adopt the plan to fold it into a new Administration for a Healthy America. That is a real, if modest, vote of confidence in the boring machinery. But the stopgap funding expires December 11, none of the twelve FY27 bills is law, and a flat SAMHSA budget does not offset what happens if tens of thousands of people with substance use disorders lose the Medicaid card that pays for their buprenorphine.

What the decline is actually standing on

Go back to Charlotte. The team that finally reached Cromartie’s son — Atrium Health’s Post Overdose Response Team — is funded with Mecklenburg County’s opioid settlement money and staffed with peer specialists who are themselves in recovery. “If somebody makes a call to us, we’re reaching out immediately within the first 24 hours,” Dr. Christopher Griggs, the team’s co-medical director, told WSOC. That is the real anatomy of the decline, repeated in hundreds of counties: someone survives an overdose, someone who has been there shows up fast, and something pays for the medication that follows. Usually that something is Medicaid.

“If somebody makes a call to us, we’re reaching out immediately within the first 24 hours,” Dr.

None of it makes for a good press release. It also isn’t fragile in the way a drug seizure is fragile — it compounds. Every person kept alive and connected this year is a person who might be the peer specialist in 2030. Jennifer Oram is five years into her own recovery. The decline we are celebrating is partly made of people like her, who got a door held open long enough to walk through it.

If you are a provider reading this, here is the move for this week, not next quarter: pull your list of Medicaid patients and make sure every chart documents the substance use disorder diagnosis and active treatment in language a state eligibility worker will recognize as a medical frailty exemption. Confirm the mailing address and phone number for each of them before January. And ask your state Medicaid agency — in Arizona, AHCCCS — directly, in writing, whether it intends to take the federal hold-harmless option. A question on the record is harder to ignore than a hold queue.

If you are someone in recovery or still using, here is what is still yours tonight, no matter who wins the credit fight. Naloxone has been sold over the counter since the FDA approved it for nonprescription use in 2023; you do not need anyone’s permission to carry it. Your Medicaid coverage does not end on January 1 because a rule starts that day — and if you are in treatment, the law says you are supposed to be protected. Make your provider prove they’ve written it down.

The White House wants the decline to be a story about a war that was won. It is a story about a mother who refused to stop calling, a peer specialist who answered, and a Medicaid card that paid for what came next. Cut the last part and the first two stop working. We have already seen what this country does with a decline it doesn’t understand. This time we know exactly who did the work. The only question is whether we keep paying them.

Read more on the national trend in The Crisis, By the Numbers, our opioids hub, and our earlier look at the stimulant gap hiding inside the opioid decline.

Filed Under

policytrendstreatmentOverdoseGovernment DataCMS / MedicaidFederalPeer SupportOpioid SettlementFamilies & CaregiversFentanyl

Keep up with the reporting.

One email each morning with the stories that put days like this in context.

A daily, no-spam briefing. Unsubscribe anytime.

Continue reading

More from this section